LETTER FROM THE CHAIRMAN

On behalf of the current and proposed board of Directors of your
company, I am delighted to offer you this opportunity to invest in
VosTech Limited (VosTech or Company) and participate in the future
potential of the Company's new biotechnology acquisitions.

Subject to approval by the Company's shareholders at the General
Meeting being convened on 12 August 2002, VosTech will make offers to
acquire 100% of the capital of Brightsun, an animal biotechnology
company.

Brightsun is focussing on the research, development and
commercialisation of biological solutions for both companion and
production animals. The aim of these biological solutions is to
improve the health and welfare of animals, increase productivity at
an economical cost, and reduce the use of chemicals and drugs,
particularly antibiotics, in production animals.

Increasing awareness of the influence of chemical and antibiotic
residues on human health, animal health and the human food chain, and
the emergence of drug and chemical resistance, dictates that more
acceptable alternative solutions to animal healthcare problems are
developed to reduce the widespread and often detrimental use of these
chemicals and drugs.

The use of certain antibiotics in food producing animals is already
subject to regulation, with some additives prohibited in certain
countries reflecting the acknowledgment of the role of residues from
meat or poultry meat in the development of antibiotic resistance in
bacterial diseases of humans, or the so-called "superbugs".

The initial projects that Brightsun has identified are the result of
years of dedicated research by the research teams at both the
Livestock Industries division at the Commonwealth Scientific and
Industrial Research Organisation (CSIRO) and the Division of
Veterinary and Biomedical Sciences at Murdoch University.

The initial production animal solutions are targeting the pig and
poultry health products markets world-wide which are estimated to be
in excess of US$8 billion per annum. These solutions comprise a
vaccine delivery system, specific vaccines targeting commercially
important diseases and biotherapeutics and productivity enhancers
that aim to replace the current antibiotic usage.

The initial companion animal solution under development is for an
efficient and biological flea control vaccine. The current companion
animal flea control product global market is estimated at US$2
billion per annum, the dominant products being either chemically
based or having low rates of efficacy.

The production animal solutions are at an advanced stage of
development with a number of key patents granted in the USA and other
developed countries, with others under application. Milestone based
commercial understandings with major veterinary pharmaceutical
companies have been reached, although not executed, for the
evaluation and development of certain products in specific geographic
areas.

The acquisition of Brightsun provides access to these well
established biotechnology projects. These projects aim to improve
disease or parasite control in animals and poultry, reduce the use of
harmful chemicals and drugs, and reduce the level of chemical and
antibiotic residue entering the human food chain. The potential and
existing markets for these products is large, with the opportunity
for these new products to replace existing products and create new
markets. The products are all biologically based.

The capital raised pursuant to the Offers contained within this
Prospectus will be utilised in furthering the Company's development
of its existing technology and the biotechnology investments to be
acquired as a result of the Brightsun transactions.

I recommend this investment opportunity to you.

D Steinepreis
CHAIRMAN